Wealth Effects LLC Has $339,000 Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Wealth Effects LLC reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 12.1% during the third quarter, Holdings Channel.com reports. The fund owned 14,500 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the period. Wealth Effects LLC’s holdings in TG Therapeutics were worth $339,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Marshall Wace LLP bought a new position in TG Therapeutics during the 2nd quarter worth approximately $36,501,000. Hood River Capital Management LLC acquired a new stake in shares of TG Therapeutics during the first quarter worth $22,420,000. Point72 Asset Management L.P. bought a new position in TG Therapeutics during the second quarter worth $10,423,000. Assenagon Asset Management S.A. acquired a new position in TG Therapeutics in the second quarter valued at $8,698,000. Finally, Vanguard Group Inc. lifted its holdings in TG Therapeutics by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 13,670,944 shares of the biopharmaceutical company’s stock valued at $233,500,000 after buying an additional 199,770 shares during the period. 58.58% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on TGTX. HC Wainwright reissued a “buy” rating and issued a $49.00 price objective on shares of TG Therapeutics in a research report on Wednesday, September 18th. B. Riley lifted their target price on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group boosted their price target on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $31.83.

TG Therapeutics Stock Up 2.1 %

TG Therapeutics stock traded up $0.48 during midday trading on Monday, reaching $23.79. The stock had a trading volume of 1,025,079 shares, compared to its average volume of 3,648,268. The company has a fifty day moving average price of $23.19 and a two-hundred day moving average price of $19.35. TG Therapeutics, Inc. has a 12 month low of $6.52 and a 12 month high of $26.41. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $3.68 billion, a P/E ratio of 101.35 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.08. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The firm had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. During the same quarter in the previous year, the company posted ($0.34) earnings per share. The company’s quarterly revenue was up 357.0% on a year-over-year basis. As a group, equities analysts expect that TG Therapeutics, Inc. will post 0.13 EPS for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.